Eisai Email Format

Pharmaceutical Manufacturing
1,001-2,500 employees
Nutley, NJ, USA

Eisai is a global pharmaceutical company focused on oncology and neurology, developing innovative therapies to address unmet medical needs for patients worldwide.

Find contacts at Eisai

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first_last@eisai.com

Company Overview

Industry
Pharmaceutical Manufacturing
Founded
1941
Headquarters
Nutley, NJ, USA
Revenue
$5B-$10B
FUNDING Stage
Public
Key Executives
Haruo Naito (Representative Corporate Officer and CEO), Takuya Oyama (Vice President Chief Financial Officer Chief IR Officer), Keisuke Naito (Representative Corporate Officer, Executive Vice President, COO, Chief Growth Officer)

Tech Stack

Salesforce

CRM

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Eisai?

Eisai uses the first_last format, so Jane Smith would be jane_smith@eisai.com.

What are Eisai's two primary therapeutic areas of focus?

Eisai concentrates on neurology and oncology as its core areas of expertise. Within neurology, Eisai is particularly active in Alzheimer's disease and sleep disorders, while its oncology work includes treatments like LENVIMA for cancers such as renal cell carcinoma and endometrial cancer.

How is LEQEMBI positioned within Eisai's neurology portfolio?

LEQEMBI (lecanemab) is Eisai's flagship Alzheimer's disease treatment, co-developed and co-commercialized with Biogen. Eisai leads global development and regulatory submissions, and in 2026 the therapy is projected to generate over $900 million in revenue, making it central to Eisai's neurology portfolio.

Where does Eisai conduct its research and development operations in the United States?

Eisai has maintained a US presence for nearly 40 years, with its US subsidiary Eisai Inc. headquartered in Nutley, NJ. The company runs research, development, and manufacturing operations across multiple US locations. Tools like Clay can help you find the right Eisai contact by location or team.

Who leads Eisai as its chief executive in 2026?

Haruo Naito serves as Eisai's Representative Corporate Officer and CEO in 2026. Keisuke Naito holds the role of Representative Corporate Officer, Executive Vice President, COO, and Chief Growth Officer, while Takuya Oyama serves as CFO and Chief IR Officer.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles